1 January 2024 in The Anatolian Journal of Cardiology
Hypertrophic cardiomyopathy (HCM) is a genetically inherited cardiac disorder with diverse clinical presentations. Adrenergic activity, primarily mediated through beta-adrenoceptors, plays a central role in the clinical course of HCM. Adrenergic stimulation increases cardiac contractility and heart rate through beta-1 adrenoceptor activation. Beta-blocker drugs are recommended as the primary treatment for symptomatic HCM patients to mitigate these effects. This prospective study aimed to investigate the impact of common ADRB-1 gene polymorphisms, specifically serine-glycine at position 49 and arginine-glycine at position 389, on the clinical and structural aspects of HCM. Additionally, the study explored the association between these genetic variations and the response to beta-blocker therapy in HCM patients. A cohort of 147 HCM patients was enrolled, and comprehensive assessments were performed. The findings revealed that the Ser49Gly polymorphism significantly influenced ventricular ectopic beats, with beta-blocker therapy effectively reducing them in Ser49 homozygous patients. Moreover, natriuretic peptide levels decreased, particularly in Ser49 homozygotes, indicating improved cardiac function. Left ventricular outflow obstruction, a hallmark of HCM, was also reduced following beta-blocker treatment in all patient groups. In contrast, the Arg389Gly polymorphism did not significantly impact baseline parameters or beta-blocker response. These results emphasize the role of the Ser49Gly polymorphism in the ADRB-1 gene in shaping the clinical course and response to beta-blocker therapy in HCM patients. This insight may enable a more personalized approach to managing HCM by considering genetic factors in treatment decisions. Further research with larger populations and longer follow-up periods is needed to confirm and expand upon these findings.
1 June 2022 in The Anatolian Journal of Cardiology
11 February 2026 in Echocardiography
13 November 2020 in Istanbul Medical Journal
25 April 2026 in Internal Medicine Journal
Aim: Idiopathic recurrent pericarditis (IRP) is considered an autoinflammatory disease, and interleukin 1 inhibitors, such as anakinra, are used to treat resistant cases. Constrictive pericarditis, a feared complication, continues to be a critical concern. In the biologic era, evidence on long‐term transthoracic echocardiographic (TTE) findings following anakinra treatment remains limited. Methods: We conducted a cross‐sectional study that included 18 patients with IRP treated with anakinra who had been attack‐free for at least 3 months. TTE was performed on all patients and 21 healthy controls, and findings were compared between the groups. Results: Pericardial thickness was significantly increased in patients compared with controls (3.1 mm (interquartile range (IQR): 3.0–3.4) vs 2.1 mm (IQR: 1.9–2.4), P < 0.001). None of the patients exhibited echocardiographic signs of constrictive pericarditis. Mild pericardial effusion was present in nine patients (50%) despite being attack‐free. Pericardial hyperechogenicity was observed in 61.1% of the patient group and 23.8% of the control group ( P = 0.018). In the subgroup analysis of patients receiving ongoing anakinra treatment and those who had discontinued, there were no significant differences in pericardial thickness ( P = 0.573), pericardial effusion ( P = 0.637) or pericardial hyperechogenicity ( P = 0.066). Conclusion: In conclusion, despite the refractory course of the disease, no cases of constrictive pericarditis were identified. TTE evaluation revealed increased pericardial thickness in patients who received anakinra compared with healthy controls, despite being attack‐free. Further studies are needed to clarify whether the presence of pericardial thickening or ongoing pericardial effusion should influence treatment planning.
29 September 2026 in Catheterization and Cardiovascular Interventions